Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GOLD Pushes LABA/LAMA Class In New COPD Treatment Update

Executive Summary

New guidelines for the treatment of COPD could change the way this serious condition is managed, with knock-on effects for pharma companies with respiratory franchises.

Advertisement

Related Content

Boehringer And Anthem Put Stiolto Duo To Real World Test In COPD
Sunovion To Commercialize Novartis’s COPD Products In US
Clinical Evidence Concern Over New COPD Update
Novartis's FLAME Rockets LAMA/LABAs Into COPD Limelight At GSK's Expense

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097750

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel